Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
10mg |
|
||
Other Sizes |
|
Targets |
Neuropilin-1[2]
|
---|---|
ln Vitro |
ATWLPPR Peptide TFA is a neuropilin-1 inhibitor that selectively blocks VEGF165 binding to NRP-1, with an 82% inhibition at 100 μM[1].
|
ln Vivo |
ATWLPPR (400 μg/kg, sc) protects vascular integrity, lowers oxidative stress, and may lessen diabetes's early-onset retinal damage[2]. GFAP, VEGF, and ICAM-1 are three proteins linked to inflammation that ATWLPPR inhibits from rising in the retina[2].
|
References |
[1]. Starzec A, et al. Structure-function analysis of the antiangiogenic ATWLPPR peptide inhibiting VEGF(165) binding to neuropilin-1 and molecular dynamics simulations of the ATWLPPR/neuropilin-1 complex. Peptides. 2007 Dec;28(12):2397-402.
[2]. Wang J, et al. The Neuropilin-1 Inhibitor, ATWLPPR Peptide, Prevents Experimental Diabetes-Induced Retinal Injury by Preserving Vascular Integrity and Decreasing Oxidative Stress. PLoS One. 2015 Nov 10;10(11):e0142571. |
Molecular Formula |
C42H62F3N11O11
|
---|---|
Molecular Weight |
954.00
|
Related CAS # |
ATWLPPR Peptide;272121-15-0
|
Solubility (In Vitro) |
H2O :~100 mg/mL (~104.82 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (104.82 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
 (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.0482 mL | 5.2411 mL | 10.4822 mL | |
5 mM | 0.2096 mL | 1.0482 mL | 2.0964 mL | |
10 mM | 0.1048 mL | 0.5241 mL | 1.0482 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.